Zai Lab Limited (HKG:9688)
Hong Kong
· Delayed Price · Currency is HKD 29.65
+1.10 (3.85%)
Jun 6, 2025, 4:08 PM HKT
Zai Lab Employees
Zai Lab had 1,869 employees as of December 31, 2024. The number of employees decreased by 306 or -14.07% compared to the previous year.
Employees
1,869
Change (1Y)
-306
Growth (1Y)
-14.07%
Revenue / Employee
1.74M HKD
Profits / Employee
-1.05M HKD
Market Cap
31.10B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| BeOne Medicines | 11,000 |
| Hansoh Pharmaceutical Group Company | 8,989 |
| JD Health International | 3,564 |
| Innovent Biologics | 5,659 |
| WuXi Biologics | 12,575 |
| CSPC Pharmaceutical Group | 21,400 |
| Sino Biopharmaceutical | 24,379 |
| Sichuan Kelun-Biotech Biopharmaceutical | 1,837 |
Zai Lab News
- 4 days ago - NovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer Trial - Benzinga
- 4 days ago - Zai Lab Presents Positive Phase 1 Data for ZL-1310, a DLL3-Targeted ADC, Demonstrating Robust Anti-Tumor Activity and Safety in Patients with Extensive-Stage Small Cell Lung Cancer at 2025 ASCO Annual Meeting - Business Wire
- 6 days ago - Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting - Business Wire
- 7 days ago - Zai Lab Announces Participation in Investor Conferences in June 2025 - Business Wire
- 9 days ago - Zai Lab Limited Is Well Positioned For Long-Term Growth - Seeking Alpha
- 15 days ago - Zai Lab Limited: Banking On Chinese Pharma Growth - Seeking Alpha
- 18 days ago - Zai Lab gets FDA fast track status for lung cancer treatment - Seeking Alpha
- 18 days ago - Zai Lab Receives U.S. FDA Fast Track Designation for ZL-1310, a DLL3-Targeted Antibody-Drug Conjugate, for Treatment of Extensive-Stage Small Cell Lung Cancer - Business Wire